Neurocrine Biosciences NBIX
NASDAQ NBIX
$174.41 +5.27 (+3.12%)
At close: Nov 11, 2026 · 4:00 PM EST

Neurocrine Biosciences (NBIX) Gains (Losses) on Sale of Assets & Investments (2009 - 2026)

Updated

Analysis

Neurocrine Biosciences (NBIX) Gains (Losses) on Sale of Assets & Investments (2009 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Neurocrine Biosciences 17.13 Bn 13.21 Bn 1.10 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 28.60 Mn
Dec 31, 2025 4.00 Mn
Dec 31, 2024 1.90 Mn
Sep 30, 2024 -16.90 Mn
Jun 30, 2024 -19.90 Mn
Mar 31, 2024 -1.60 Mn
Dec 31, 2023 -29.00 Mn
Sep 30, 2023 -40.10 Mn
Jun 30, 2023 37.30 Mn
Dec 31, 2022 -54.40 Mn
Sep 30, 2022 11.10 Mn
Jun 30, 2022 -7.40 Mn
Mar 31, 2022 19.90 Mn
Dec 31, 2021 28.40 Mn
Sep 30, 2021 -8.20 Mn
Mar 31, 2021 700,000.00
Dec 31, 2020 -5.50 Mn
Sep 30, 2020 -7.00 Mn
Jun 30, 2020 11.30 Mn
Mar 31, 2020 -16.50 Mn
API Access

Neurocrine Biosciences Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=NBIX&period=max&api_key=YOUR_API_KEY